Showing results (771-780 of 1,351) with videos related to
Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|February 19, 2020
Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic DosingWeiguo Cai, Tarek A Leil, Leonid Gibiansky, et al.Clinical Pharmacology in Drug Development|March 6, 2020
Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy VolunteersSalvatore Febbraro, Tim Shea, Ana Santos CravoClinical Pharmacology in Drug Development|June 17, 2022
Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020Xiaofei Wu, Fan Zhang, Mengyang Yu, et al.Clinical Pharmacology in Drug Development|December 12, 2022
Single-dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal ImpairmentRamesh Boinpally, Darren WeissmanClinical Pharmacology in Drug Development|July 24, 2020
Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy ParticipantsAdedayo Adedoyin, Craig Fancourt, Karsten Menzel, et al.Clinical Pharmacology in Drug Development|August 10, 2020
Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended-Release TabletsAbdel Qader Al Bawab, Bashar A Alkhalidi, Esra'a Albarahmieh, et al.Clinical Pharmacology in Drug Development|August 22, 2020
Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy VolunteersSeyed Reza Khandoozi, Majid Shahbazi, Hossein AminiClinical Pharmacology in Drug Development|April 10, 2023
Pharmacokinetics and Safety Evaluation of Maribavir in Healthy Japanese and Matched White Participants: A Phase 1, Open-Label StudyIvy Song, Ben Suttle, Jingyang Wu, et al.Clinical Pharmacology in Drug Development|April 19, 2023
Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group StudyRajinder Bhardwaj, Andrea Ivans, Joseph Stringfellow, et al.Clinical Pharmacology in Drug Development|October 11, 2022
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy VolunteersNaoto Yamakawa, Fumitoshi Tago, Kenya Nakai, et al.Pageof 136